Table 2.
Examples of different types of naked antibody compound patents
| Category | Example IP right | Assignee | Target | Claim language |
|---|---|---|---|---|
| Antibody claimed by its target or target epitope | EP1587837B1 | Proscan RX | PSMA | An antigen comprising an immunogenic moiety or carrier and an epitope of the extracellular region of PSMA consisting of SEQ ID NO:8, wherein the N-terminal cysteine residue on SEQ ID NO:8 is optional. An isolated antibody or antigen binding fragment thereof, which binds to the antigen wherein the antibody and/or antigen binding fragment thereof also binds to PSMA. |
| Antibody claimed by functional properties | EP1347730B2 | Seattle Genetics | CD30 | An antibody that immunospecifically binds CD30 and exerts a cytostatic or cytotoxic effect on a Hodgkin's disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent. |
| Antibody claimed by expressor cell | EP0660721B1* | Dana Farber | CD22 | A monoclonal antibody that: is produced by a hybridoma cell line selected from the group consisting of HB22–7 (ATCC No. HB 11347), HB22–22 (ATCC No. HB 11348) and HB22–23 (ATCC No. HB11349) […] |
| Antibody claimed by sequence | EP0590058B1* | Genentech | HER2 | A humanized Antibody which comprises a VL domain comprising the polypeptide sequence X and a VH domain comprising the polypeptide sequence Y. |
| Antibody claimed by sequence | EP1951757B1 | Xencor | CD30 | An anti-CD30 antibody, comprising a variable heavy chain sequence 1 and a variable light chain sequence 2 |
*
expired; the symbol […] indicates that claim language has been truncated.